key: cord-0950362-t5c2616r authors: Abd El-Aziz, Nourhan M.; Khalifa, Ibrahim; Darwish, Amira M. G.; Badr, Ahmed N.; Aljumayi, Huda; Hafez, El-Sayed; Shehata, Mohamed G. title: Docking Analysis of Some Bioactive Compounds from Traditional Plants against SARS-CoV-2 Target Proteins date: 2022-04-20 journal: Molecules DOI: 10.3390/molecules27092662 sha: 5c5eec06b57a114635675b37e3c062876a51f2ce doc_id: 950362 cord_uid: t5c2616r COVID-19 is still a global pandemic that has not been stopped. Many traditional medicines have been demonstrated to be incredibly helpful for treating COVID-19 patients while fighting the disease worldwide. We introduced 10 bioactive compounds derived from traditional medicinal plants and assessed their potential for inhibiting viral spike protein (S-protein), Papain-like protease (PLpro), and RNA dependent RNA polymerase (RdRp) using molecular docking protocols where we simulate the inhibitors bound to target proteins in various poses and at different known binding sites using Autodock version 4.0 and Chimera 1.8.1 software. Results found that the chicoric acid, quinine, and withaferin A ligand strongly inhibited CoV-2 S -protein with a binding energy of −8.63, −7.85, and −7.85 kcal/mol, respectively. Our modeling work also suggested that curcumin, quinine, and demothoxycurcumin exhibited high binding affinity toward RdRp with a binding energy of −7.80, −7.80, and −7.64 kcal/mol, respectively. The other ligands, namely chicoric acid, demothoxycurcumin, and curcumin express high binding energy than the other tested ligands docked to PLpro with −7.62, −6.81, and −6.70 kcal/mol, respectively. Prediction of drug-likeness properties revealed that all tested ligands have no violations to Lipinski’s Rule of Five except cepharanthine, chicoric acid, and theaflavin. Regarding the pharmacokinetic behavior, all ligand predicted to have high GI-absorption except chicoric acid and theaflavin. At the same way chicoric acid, withaferin A, and withanolide D predicted to be substrate for multidrug resistance protein (P-gp substrate). Caffeic acid, cepharanthine, chicoric acid, withaferin A, and withanolide D also have no inhibitory effect on any cytochrome P450 enzymes. Promisingly, chicoric acid, quinine, curcumin, and demothoxycurcumin exhibited high binding affinity on SARS-CoV-2 target proteins and expressed good drug-likeness and pharmacokinetic properties. Further research is required to investigate the potential uses of these compounds in the treatment of SARS-CoV-2. Coronavirus disease 2019 (COVID- 19) , the highly infectious viral illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a disastrous effect as relieving cytokines storm syndrome, protecting human tissues and organs, relieving immunological injury, and enhancing the body's ability [17] . Ayurveda, known as "The Science of Life," an ancient traditional medicinal system that originated and is practiced in India, has been utilized for reducing SARS-CoV-2 infection and treating COVID-19-associated patients [18] [19] [20] . It describes many medicinal plants and herbs possessing a broad range of therapeutic usefulness in curing various kinds of ailments, diseases, and disorders, such as Allium sativum (Garlic), W. somnifera known commonly as ashwagandha, Zingiber officinale Roscoe (Ginger), Tinospora cordifolia (Giloy), Ocimum sanctum (Tulsi), Curcuma longa (Turmeric, Haldi), Glycyrrhiza glabra (Licorice, mulethi), and others [20] [21] [22] . In this study we aim to investigate docking characteristics of 10 bioactive compounds identified from traditional medicines (caffeic and chicoric acids from Echinacea purpurea; xanthorrhizol from Java turmeric; curcumin and demothoxycurcumin from Curcuma longa L.; Quinine from Chinchona bark; Theaflavin from Black tea; withaferin A and withanolide D from Withania somnifera L.; cepharanthine from Stephania cepharantha) on S-protein, RdRp and SARS-CoV-2 PLpro to explore the potential mode of the inhibitory activity toward SARS-CoV-2. The molecules that showed better hydrogen bonding and binding energy were selected further for drug likeness and pharmacokinetics prediction. Herbal medicines and medicinal plant-based natural compounds provide a rich resource for novel antiviral drug development. Some natural medicines have been shown to possess antiviral activities against various virus strains including coronavirus, herpes simplex virus [23] [24] [25] , influenza virus [25] , human immunodeficiency virus [26] , hepatitis B and C viruses [27] , SARS, and MERS [28, 29] . These compounds antiviral action mechanisms caused by influencing of the viral life cycle, such as viral entry, replication, assembly, and release, as well as virus-host-specific interactions. In this study we analyze the binding mode of 10 ligands Figure 1 that previously identified in some traditional plants Table 1 using computational docking analysis. All tested ligands showed hydrogen interaction to papain-like protease (6W9C) except cepharanthine and theaflavin. The ligand docking on CYS111, HIS272, and ASP286 catalytic residues ( Figure 2A ) ranked by binding energy ∆G in kcal/mol were as follows: chicoric acid > demothoxycurcumin > curcumin > withanolide D > xanthorrhizol > withaferin A > caffeic acid > quinine. It is known that the high binding affinity of the drug compounds depends on the type and amount of bonds occurring with the target protein [53] . The binding energies were −7.62, −6.81, −6.70, −6.58, −6.16, −6.13, −5.70, and −5.67 kcal/mol, respectively (Table 2; Figure 3 ). The first reported bioactive effect of chicoric acid is its ability to inhibit infection with human immunodeficiency virus 1 (HIV-1) [54] . Several studies reported that chicoric acid inhibits infection with HIV-1 by deactivating the HIV-1 integrase. HIV-1 integrase is a multidomain enzyme required for integration of viral DNA into the host genome, a critical step in viral replication [55] . Inhibition of HIV-1 integration by chicoric acid results in stopping virus replication, leading to increased T-lymphoblastoid cell viability [56] . Chicoric acid found in many Egyptian source as Chicory and Echinacea purpurea ( Table 1 ). Despite that cepharanthine (CEP) showed no binding behavior toward papain-like protease, it has unique anti-inflammatory, antioxidative, immunomodulating, antiparasitic, and antiviral properties. It can suppress nuclear factor-kappa B (NF-κB) activation, lipid peroxidation, nitric oxide (NO) production, cytokine production, and expression of cyclooxygenase; all of which are crucial to viral replication and inflammatory response [33] . Against SARS-CoV-2 and homologous viruses, CEP predominantly inhibits viral entry and replication at low doses [57] . chicoric acid > demothoxycurcumin > curcumin > withanolide D > xanthorrhizol > withaferin A > caffeic acid > quinine. It is known that the high binding affinity of the drug compounds depends on the type and amount of bonds occurring with the target protein [53] . The binding energies were −7.62, −6.81, −6.70, −6.58, −6.16, −6.13, −5.70, and −5.67 kcal/mol, respectively (Table 2; Figure 3 ). Moreover, all tested ligands showed H-interaction to spike protein (6M17). The ligand docking on GLY 502, TYR 489 and TYR 505 ( Figure 2B ) ranked by binding energy in kcal/mol were as follows: chicoric acid > quinine = withaferin A > withanolide D > theaflavin > demothoxycurcumin > curcumin > xanthorrhizol > cepharanthine > caffeic acid. The binding energies were −8.63, −7.85, −7.85, −7.78, −7.43, −7.23, −6.34, −6.00, −5.26 and −5.06 kcal/mol respectively (Table 2; Figure 4 ). Cepharanthine (CEP) is a natural alkaloid, which has been widely used to treat many of the acute and chronic diseases. It is usually used in Japan in the form of Stephania cepharantha and Stephania rotunda (Table 1) for its anti-inflammatory, antiparasitic, anti-oxidative, antiviral, and anti-HIV activities [32] [33] [34] [35] . In 2021 a Japanese research team reported the anti-COVID-19 activity of the combining cepharanthine/nelfinavir providing synergistic antiviral effects that CEP and nelfinavir inhibit SARS-CoV-2 entry and RNA replication, respectively [58] . In 2021, a Japanese research team reported that the combination of cepharanthine and nelfinavir inhibited SARS-CoV-2 entrance and RNA replication, offering synergistic antiviral effects [58] . flammatory, antiparasitic, anti-oxidative, antiviral, and anti-HIV activities [32] [33] [34] [35] . In 2021 a Japanese research team reported the anti-COVID-19 activity of the combining cepharanthine/nelfinavir providing synergistic antiviral effects that CEP and nelfinavir inhibit SARS-CoV-2 entry and RNA replication, respectively [58] . In 2021, a Japanese research team reported that the combination of cepharanthine and nelfinavir inhibited SARS-CoV-2 entrance and RNA replication, offering synergistic antiviral effects [58] . This previous combination based on in silico docking simulation that confirms that CEP molecule can bind to SARS-CoV-2 S-protein and interfere with the spike engagement to its receptor, angiotensin-converting enzyme 2 (ACE2) [59, 60] . Our results strongly supported this mechanism of CEP toward SARS-CoV-2 S-protein. However, chicoric acid, quinine, withaferin A, withanolide D, theaflavin, demothoxycurcumin, curcumin, and xanthorrhizol expressed higher binding energy than cepharanthine in case SARS-CoV-2 S-protein binding. From all of this we supposed that chicoric acid and quinine may play the same role in this combination (cepharanthine/nelfinavir) beside their acting mechanism toward SARS-CoV-2, PLpro and RdRp that may be promising to limit SARS-CoV-2 proliferation than CEP. Regarding to RdRp (6M71), all tested ligands showed H-interaction except Cepharanthine. The ligand docking on ARG 553, ARG 555, LYS 545, and ASN 691 ( Figure 2C ) ranked by binding energy ∆G in kcal/mol were as follows: curcumin = quinine > demothoxycurcumin > chicoric acid > caffeic acid > withaferin A > withanolide D > xanthorrhizol > theaflavin. The binding energies were −7.80, −7.80, −7.64, −7.50, −6.75, −6.27, −6.10, −5.33, and −2.55 kcal/mol, respectively (Table 2; Figure 5 ). proliferation than CEP. Regarding to RdRp (6M71), all tested ligands showed H-interaction except Cepharanthine. The ligand docking on ARG 553, ARG 555, LYS 545, and ASN 691 ( Figure 2C ) ranked by binding energy ΔG in kcal/mol were as follows: curcumin = quinine > demothoxycurcumin > chicoric acid > caffeic acid > withaferin A > withanolide D > xanthorrhizol > theaflavin. The binding energies were −7.80, −7.80, −7.64, −7.50, −6.75, −6.27, −6.10, −5.33, and −2.55 kcal/mol, respectively (Table 2; Figure 5 ). Curcumin (CC) and its analogues are the main phytonutrients of turmeric (Curcuma longa L.) and other Curcuma spp., which are widely used around the world as culinary Curcumin (CC) and its analogues are the main phytonutrients of turmeric (Curcuma longa L.) and other Curcuma spp., which are widely used around the world as culinary spices, traditional medicine as well as a popular dietary supplement ingredient due to its wide range of health benefits including anti-inflammation [61] , anti-cancer [62] , cardiovascular regulation [63] , respiratory [64] , and immune system benefits [65] . In addition, the suppression of multiple cytokines by curcumin suggested that it may be a useful approach in treating Ebola patients against cytokine storm [66] . As severe cases of COVID-19 are often associated with cytokine release syndrome, the use of anti-inflammatory molecules may reduce the proinflammatory cytokines involved. Quinine, is an extract of the bark of the Chinchona tree (native to the Andes of South America), that was used to treat feverish infections, particularly malaria, for hundreds of years almost worldwide [67] . Curcuma longa L. and Chinchona bark are rich source of curcumin and quinine respectively (Table 1) . Table 3 presents the drug likeness and pharmacokinetic properties of the tested ligands. Lipinski's Rule of Five is generally used as an indicator of the drug likeness and pharmacological activities. In humans, this would make them orally active medications [68] . All the tested compounds are in the molecular weight range of 180.16 to 474.37 Da (<500 Da), except for cepharanthine and theaflavin are 606.71 and 564.49 Da. It is well known that drug molecules typically have low molecular weight (<500 kDa) are transported, diffused, and absorbed easily compared with large molecules [69] . All the tested compounds also have fewer than 15 rotatable bonds, and all have less than 5 hydrogen bond donors (NH and OH), except for quinine and theaflavin. In addition, the numbers of hydrogen bond acceptors (O and N atoms) predicted in all compounds are less than 10, except for chicoric acid and theaflavin (Table 3) . At the same time, permeability (logP) of these ligands has also been investigated, and it was found that these ligands exhibited logP values of less than 5 except cepharanthine. Moreover, the topological polar surface area (TPSA) values of all ligands are less than 140 Å, except for chicoric acid and theaflavin. TPSA is closely related to the H-bonding ability of a compound [70] . The TPSA and the logP values are the two essential characteristics in the analysis of the bioavailability of drug molecules and permeability toward bio-membranes [71] . Compounds with 10 rotatable bonds and TPSA of ≤140 Å can be predicted to have good bioavailability [72] . As a result, all of the ligands examined have good bioavailability, with the exception of chicoric acid and theaflavin, which have TPSA values of 208.12 and 217.60, respectively. Pharmacokinetic prediction provides information to evaluate the time course of drugs and their effects on the body to design an appropriate drug regimen for any patient [73] . Our results of pharmacokinetic prediction (Table 3) showed that all tested ligands demonstrate a high absorption rate in the GI tract, except for chicoric acid and theaflavin. Moreover, none of the tested ligands were predicted to be able to pass through the bloodbrain barrier, except for quinine and xanthorrhizol. Additionally, chicoric acid, withaferin A and withanolide D are the only compounds predicted to act as a substrate for P-gp, which decrease their further clinical application [74] . The predicted pharmacokinetic behavior indicates that only caffeic acid, cepharanthine, chicoric acid, withaferin A, and withanolide D would have no inhibitory effect on any cytochrome P450 enzymes (CYP1A2, CYP2C19, CYP2D6, and CYP3A4). Furthermore, CYP2C9 activity is only known to be affected by curcumin, demothoxycurcumin, theaflavin and xanthorrhizol. Cytochrome P450 enzymes are essential for the metabolism of many chemicals. Although this class contains more than 50 enzymes, six of them metabolize 90% of compounds. Cytochrome P450 enzyme inhibition causes unwanted adverse effects or therapeutic failures [75] . The proposed mechanism of SARS-CoV-2 inhibition by tested compounds is summarized in Figure 6 ; chicoric acid, quinine and withaferin A, interacting with S protein, inhibits viral ability to attach to human ACE2. Additionally, chicoric acid, demothoxycurcumin, and curcumin interacting with PL pro, inhibits viral replication, moreover, curcumin, demothoxycurcumin, and quinine interacting with RdRp, inhibits viral replication. Furthermore, interferon (IFN) production is triggered by virus infections that cause accumulation of RNA species in the cytoplasm, initiate the oligomerization of an essential mitochondrial antiviral signaling protein, MAVS, that serves as a scaffold for the activation of TNF receptor-associated factor (TRAF) family proteins, TRAF2, TRAF3, TRAF5, and TRAF6. TRAF proteins catalyze the assembly of K63-linked ubiquitin chains that are required for the activation of serine kinases, IKKa, IKKb, IKKc, IKKe, and TBK1. Kinase activation triggers the phosphorylation and nuclear import of IRF3, driving the production of primary antiviral effectors including IFNs [76] . On the other hand, PLpro of SARS-CoV-2 interfere with innate immune response by directly cleaving IRF3, inhibits IFNβ production. In general, in silico studies are a great starting point when looking for new therapeutic targets. In the event of an unpredictable pandemic, such as the recent COVID-19 epidemic, in silico research are critical. Drug targets cannot be discovered in a short period of time using existing methods. To reach bulk targets, it is unavoidable to have extremely rapid procedures. In silico approaches can be used to speed up the search for drug targets in natural medicinal plants. This article's results warrant further evaluation of the potential anti-SARS-CoV-2 activity of these ligands in vitro. Molecules 2021, 26, x 12 of 16 activation triggers the phosphorylation and nuclear import of IRF3, driving the production of primary antiviral effectors including IFNs [74] . In blue: PLpro of SARS-CoV-2 interfere with innate immune response by directly cleaving IRF3, inhibits IFNβ production. Figure 6 . The proposed mechanism of SARS-CoV-2 inhibition by tested compounds. The structure of the SARS-CoV-2 papain-like protease (6W9C), RNA-dependent RNA polymerase (6M71), and spike protein (6M17) used as a target for ligands binding was downloaded from RCSB website [77] . PDB (Protein Data Bank) has enabled breakthroughs in research, such as this study, and education worldwide [78] . The three-dimensional (3D) structures of all tested ligands were drawn in ACD/ChemSketch and then docked into the rigid binding pocket of 6W9C, 6M71, and 6M17 of SARS CoV-2. The compounds used in the present study were caffeic acid, Steps from one to six describe the replication cycle of SARS-CoV-2; attachment (1), viral entry (2), translation of viral proteins (3), viral replication (4), assembly (5) , and release (6). In red: chicoric acid, quinine, and withaferin A, interacting with S protein, inhibiting its viral ability to attach to human ACE2 (1). Additionally, chicoric acid, demothoxycurcumin, and curcumin interacting with PL pro inhibits viral replication (2), moreover, curcumin, demothoxycurcumin, and quinine interacting with RdRp inhibits viral replication (3). Interferon (IFN) production is triggered by virus infections that cause accumulation of RNA species in the cytoplasm, initiating the oligomerization of an essential mitochondrial antiviral signaling protein, MAVS, which serves as a scaffold for the activation of TNF receptor-associated factor (TRAF) family proteins, TRAF2, TRAF3, TRAF5, and TRAF6. TRAF proteins catalyze the assembly of K63-linked ubiquitin chains that are required for the activation of serine kinases, IKKa, IKKb, IKKc, IKKe, and TBK1. Kinase activation triggers the phosphorylation and nuclear import of IRF3, driving the production of primary antiviral effectors including IFNs [74] . In blue: PLpro of SARS-CoV-2 interfere with innate immune response by directly cleaving IRF3, inhibits IFNβ production. The structure of the SARS-CoV-2 papain-like protease (6W9C), RNA-dependent RNA polymerase (6M71), and spike protein (6M17) used as a target for ligands binding was downloaded from RCSB website [77] . PDB (Protein Data Bank) has enabled breakthroughs in research, such as this study, and education worldwide [78] . The three-dimensional (3D) structures of all tested ligands were drawn in ACD/Chem-Sketch and then docked into the rigid binding pocket of 6W9C, 6M71, and 6M17 of SARS CoV-2. The compounds used in the present study were caffeic acid, cepharanthine, chicoric acid, curcumin, demothoxycurcumin, quinine, theaflavin, withaferin a, withanolide d and xanthorrhizol. The drug likeness and pharmacokinetic properties were calculated using the SWISSADME prediction website (http://www.swissadme.ch/) (accessed on 15 December 2021) [68, 79] . Figure 1 shows the structure of the 10 docked ligands we used herein. Table 4 contains the amino acids binding hits of the SARS-CoV-2 polymerase as described by Afonine et al. [80] , papain-like protease (6W9C) as described by Baez-Santos et al., 2015 and spike protein (6M17) as described by Baig et al. [7] . Ligand optimization was performed using Open Babel, converting ligands from mol into the PDB format. Autodock version 4.0 was used for protein optimization through the removal of water and other atoms and then addition of a polar hydrogen group. Ligand tethering of the protein was performed by regulating the genetic algorithm (GA) parameters using 10 runs of the GA criteria. Docking analyses and determination of hydrogen bonds (H-bonds) were conducted using Chimera 1.8.1 [81] . Antiviral treatments targeting the coronavirus disease 2019 are urgently required. We screened a panel of ligands from traditional plant sources already used in medicinal fields and some of them described for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Chicoric acid, quinine, curcumin, and demothoxycurcumin exhibited high binding affinity on SARS-CoV-2 S-protein, PLpro, and RdRp. Binding of these proteins interfere with the viral entry, replication, and immune response evasion. Therefore, these compounds may have a great potential for inhibiting the virus. Our work provides data about the ligand mechanism toward SARS-CoV-2 target proteins and allows the comparison between them based on scientific information. Further in vitro cell-based investigations will be needed for chicoric acid, quinine, curcumin, and demothoxycurcumin compounds to confirm their previous results and determine their antiviral mechanism at cell level. Zika Virus: Novel Guanosine Derivatives revealed strong binding and possible inhibition of the polymerase A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin Structure, function, and evolution of coronavirus spike proteins Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Expression and regulation of the neutral amino acid transporter B0AT1 in rat small intestine Identification of a Potential Peptide Inhibitor of SARS-CoV-2 Targeting its Entry into the Host Cells Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity Structurally-defined deubiquitinase inhibitors provide opportunities to investigate disease mechanisms The SARS coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds Deubiquitination, a new function of the severe acute respiratory syndrome coronavirus papainlike protease Recognition of Lys48-linked di-ubiquitin and deubiquitinating activities of the SARS coronavirus papain-like protease Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV Inhibition of the SARS-CoV-2 RNA-Dependent RNA Polymerase by Natural Bioactive Compounds: Molecular Docking Analysis Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid™ COVID-19: UK becomes first country to authorise antiviral molnupiravir Traditional Chinese medicine contributes to the treatment of COVID-19 patients. Chin. Herb Self-reported psychological distress during the COVID-19 outbreak in Nepal: Fndings from an online survey Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled, study (SHADE study) Biotechnological interventions in Withania somnifera (L.) dunal COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics Herbal Immunomodulators-A remedial panacea for designing and developing effective drugs and medicines: Current scenario and future prospects Hepatitis C virus and natural compounds: A new antiviral approach? Viruses Antiviral flavonoids from the root bark of Morus alba L The cranberry extract oximacro exerts in vitro virucidal activity against influenza virus by interfering with hemagglutinin A new anti-HIV triterpene from Geum japonicum Dehydrojuncusol, a natural phenanthrene compound extracted from Juncus maritimus, is a new inhibitor of hepatitis C virus RNA replication Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus Effective inhibition of MERS-CoV infection by resveratrol Caffeic acid oligomers from Mesona chinensis and their in vitro antiviral activities Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy Cepharanthine: An update of its mode of action, pharmacological properties and medical applications Antiviral activity of cepharanthine against severe acute respiratory syndrome coronavirus in vitro Potent inhibition of HIVtype 1 replication by an antiinflammatory alkaloid cepharanthinein chronically infected monocytic cells Optimization of the chromatographic determination of polyphenols in the aerial parts of Cichoriumintybus L Amelioration by chicory seed extract of diabetes-and oleic acid-inducednon-alcoholicfattyliverdisease(NAFLD)/non-alcoholicsteato-hepatitis (NASH) via modulkation of PPARα and SREBP-1 The Bioactive Effects of Chicoric Acid As a Functional Food Ingredient Biological activities of Curcuma longa L Curcumin, a traditional spice component, can hold the promise against COVID-19? Curcumin, a golden spice with a low bioavailability Total phenol, antioxidant and free radical scavenging activities of some medicinal plants Induction of DNA damage by the leaves and rhizomes of Curcuma amada Roxb in breast cancer cell lines Phytochemical and pharmacological properties of Curcuma amada: A Review Spectrum of biological properties of cinchona alkaloids: A brief review Anti-Cancer Properties of Theaflavins Antioxidant Activity and Main Chemical Components of a Novel Fermented Tea Exploring the Multifaceted Therapeutic Potential of Withaferin A and Its Derivatives New anti-inflammatory withanolides from Physalis pubescens fruit New withanolides with anti-inflammatory activity from the leaves of Datura metel L Metabolite profiling of Curcuma species grown in different regions using 1 HNMR spectroscopy and multivariate analysis Antimicrobial activity and essential oils of Curcuma aeruginosa, Curcuma mangga, and Zingiber cassumunar from Malaysia. Asian Pac Potential Inhibitor of COVID-19 Main Protease (M pro ) From Several Medicinal Plant Compounds by Molecular Docking Study Design, synthesis, and biological evaluation of novel hybrid dicaffeoyltartaric/diketo acid and tetrazole-substituted lchicoric acid analogue inhibitors of human immunodeficiency virus type 1 integrase Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells l-Chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro Cepharanthine: A review of the antiviral potential of a Japanese-approved alopecia drug in COVID-19 Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Curcumin targets in inflammation and cancer Curcumin use in pulmonary diseases: State of the art and future perspectives Curcumin and autoimmune disease Curcumin Suppression of Cytokine Release and Cytokine Storm. A Potential Therapy for Patients with Ebola and Other Severe Viral Infections Quinine, an old anti-malarial drug in a modern world: Role in the treatment of malaria Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Lead-and drug-like compounds: The rule-of-five revolution Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena 1. Prediction of intestinal absorption Trisubstituted pyrimidines as a new class of selective adenosine A, receptor antagonists Molecular properties that influence the oral bioavailability of drug candidates Drug metabolism and pharmacokinetic strategies for oligonucleotide-and mRNA-based drug development Ragueneau-Majlessi, I. Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects A functional C-terminal TRAF3-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response Structure of the RNA-dependent RNA polymerase from COVID-19 virus The protein data bank Evaluation of blockbuster drugs under the rule-of-five New tools for the analysis and validation of cryo-EM maps and atomic models UCSF Chimera-A visualization system for exploratory research and analysis The authors declare no conflict of interest.